Novozymes Biopharma AB of Lund, Sweden, and Upperton Ltd. of Nottingham, UK, have been granted a European patent for their targeted drug delivery technology. The patent describes methods of conjugating antibodies and other targeting agents to protein carriers by using a heterobifunctional linker, making it possible to deliver large quantities of drugs to selected sites in the body.